Drug Trial Radar · NCT07772934
VBC117First-in-Human Trial of VBC117 in Participants With Advanced Malignant Solid Tumors
Last checked: Nov 19, 2026Latest source record: Sep 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
260
Planned (sponsor's estimate)
Start
Aug 24, 2026
Primary completion
Feb 27, 2029
Study completion May 28, 2029
Sponsor
- Lead sponsor
- VelaVigo Bio IncIndustry
- Sponsor type
- Industry
- First posted
- Aug 19, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Detailed Description: This is a multicenter, open-label, multiple-dose, first in human(FIH) Phase 1/2a trial. The Phase 1 portion uses the Bayesian optimal interval (BOIN) design to escalate doses and determine the maximum tolerated dose(MTD) and/or recommended phase 2 dose(RP2D) with potential backfill cohorts. The Phase 2a portion consists of dose optimization followed by cohort expansion to confirm safety and tolerability and further evaluate the efficacy of the selected RP2D in selected solid tumor malignancies treated with VBC117.
Conditions
- Advanced Solid Tumors
Interventions
VBC117Drug
VBC117 is a epidermal growth factor receptor (EGFR)x Cadherin-17 (CDH17) bispecific antibody-drug conjugate (ADC).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of AEsTime frame: From time of Informed Consent to 30 days post last dose of VBC117
- Incidence of DLTsTime frame: From time of first dose of VBC117 to end of DLT period (approximately 21 days)
- Incidence of SAEsTime frame: From time of Informed Consent to 30 days post last dose of VBC117
- Incidence of TEAE leading to dose modification or discontinuationTime frame: From time of Informed Consent to 30 days post last dose of VBC117
- objective response rate (ORR)Time frame: From first dose of VBC117 to disease progression or death, up to approximately 2 years
Locations
12 sites in 2 countries. Site status is shown where the registry gives one.
Macquarie University
Randwick, New South Wales, Australia
Scientia Clinical Research
Randwick, New South Wales, Australia
Cancer Care Wollongong
Wollongong, New South Wales, Australia
Peninsula and South Eastern Haematology and Oncology Group
Frankston, Victoria, Australia
The Second Affiliated Hospital of Zhejiang University School of Medicine
Zhejiang, Hangzhou, China
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China
Hunan Cancer Hospital
Changsha, Hunan, China
The Second Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China
Liaoning Cancer Hospital & Institute
Shengyang, Liaoning, China
Shanghai East Hospital
Shanghai, Shanghai Municipality, China
Shanghai GoBroad Cancer Hospital
Shanghai, Shanghai Municipality, China
First Hospital of Shanxi Medical University
Taiyuan, Shanxi, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.